HIV/AIDS

Applications submitted for fixed-dose coformulation of Viread and Emtriva

Published in AIDS Weekly, April 12th, 2004

Gilead Sciences, Inc., (GILD) announced the submission of a new drug application to the U.S. Food and Drug Administration (FDA) for marketing approval of a fixed-dose coformulation of the company's anti-HIV medications Viread (tenofovir disoproxil fumarate) and Emtriva (emtricitabine).

The proposed coformulation combines Viread and Emtriva in a single pill dosed once daily, to be taken in combination with other antiretrovirals for the treatment of HIV.

The company also announced the submission of its marketing authorization application (MAA) for the fixed dose coformulation to the European Agency for the Evaluation of Medicinal Products (EMEA)....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2004-04-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry